| ［1］ Mansfield AS，Sukov WR，Eckel-Passow JE，et al. Comparison of fluorescence in situ hybridization（FISH）and dual-ISH（DISH）in the determination of HER2 status in breast cancer ［J］. Am J Clin Pathol，2013，139（2）：144-150. ［2］ Gasche JA，Goel A. Epigenetic mechanisms in oral carcinogenesis ［J］. Future Oncol，2012 ，8（11）：1407-1425. ［3］ Lim E，Metzger-Filho O，Winer EP. The natural history of hormone receptor-positive breast cancer ［J］. Oncology（Williston Park），2012，26（8）：688-694. ［4］ Khelwatty SA，Essapen S，Seddon AM，et al. Prognostic significance and targeting of HER family in colorectal cancer ［J］. Front Biosci，2013，18：394-421. ［5］ Lee HE，Park KU，Yoo SB，et al. Clinical significance of intratumoral HER2 heterogeneity in gastric cancer ［J］. Eur J Cancer，2013，49（6）：1448-1457. ［6］ Chen PC，Yu HJ，Chang YH，et al. Her2 amplification distinguishes a subset of non-muscle-invasive bladder cancers with a high risk of progression ［J］. J Clin Pathol，2013，66（2）：113-119. ［7］ Shin IY，Sung NY，Lee YS，et al. The expression of multiple proteins as prognostic factors in colorectal cancer：cathepsin D，p53，COX-2，epidermal growth factor receptor，C-erbB-2，and Ki-67 ［J］. Gut Liver，2014，8（1）：13-23. ［8］ Otsuka K，Imanishi Y，Habu N，et al. Survival analysis and immunohistochemical study of HER-2 and AR（androgen receptor）expression in salivary duct carcinoma ［J］. Nihon Jibiinkoka Gakkai Kaiho，2013，116（9）：1024-1032. ［9］ Yoon HH，Sukov WR，Shi Q，et al. HER-2/neu gene amplification in relation to expression of HER2 and HER3 proteins in patients with esophageal adenocarcinoma ［J］. Cancer，2014，120（3）：415-424. ［10］ Mahlknecht G，Maron R，Mancini M，et al. Aptamer to ErbB-2/HER2 enhances degradation of the target and inhibits tumorigenic growth ［J］. Proc Natl Acad Sci USA，2013，110（20）：8170-8175. 2013 - 12 - 16 收稿 2014 - 04 - 03 修回 本文编辑：朱冰梅 |
